Ignite Creation Date:
2024-05-05 @ 5:21 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434447
Status:
COMPLETED
Last Update Posted:
2017-02-27
First Post:
2007-02-09
Brief Title:
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer or Bone Involvement From Multiple Myeloma Assessing Long-term Efficacy and Safety
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of renal impairment osteonecrosis of the jawONJ overall safety and skeletal related events SREs beyond 12 months treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None